Skip to main content
HUALAN GROUP CO.,LTD. logo

HUALAN GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 301027 ISIN · CNE100004MH7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 662 across all filing types
Latest filing 2024-04-23 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 301027

About HUALAN GROUP CO.,LTD.

https://www.gxhl.com

Hualan Group Co., Ltd. specializes in the research, development, and manufacturing of primary pharmaceutical packaging materials. The company's core product portfolio includes high-quality butyl rubber stoppers, aluminum-plastic combination caps, and plastic components designed for injectable medications and infusion sets. These products are engineered to ensure drug stability and compatibility, meeting international quality standards such as GMP. Serving a global clientele of pharmaceutical manufacturers, the group focuses on advanced material science and precision manufacturing to provide secure sealing solutions for vaccines, antibiotics, and blood products. By integrating R&D with large-scale production capabilities, the company maintains a significant role in the pharmaceutical supply chain, emphasizing safety and reliability in drug delivery systems.

Recent filings

Filing Released Lang Actions
关于2023年计提减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by 华蓝集团股份公司 regarding the impairment provisions for the year 2023. It details the amounts of impairment provisions made, the accounting policies applied, and the impact on the company's profit. The document includes specific financial figures related to impairment testing and references compliance with accounting standards and audit confirmation. However, the document is relatively short (3004 characters) and primarily serves as a disclosure announcement about impairment provisions rather than a full financial report. It does not contain comprehensive financial statements or a full annual or interim report. It is not a certification letter, nor is it a simple notice of report publication. The content is focused on a specific accounting matter (impairment provisions) and its impact, which is typical of a Regulatory Filing (RNS) that discloses important financial information but does not constitute a full report like an Annual Report or Interim Report. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-04-23 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change in accounting policies by the company 华蓝集团股份公司. It details the reasons for the change, the specific accounting standards involved, and the impact of the change on financial statement line items for prior periods. The document does not contain a full annual or interim financial report but rather a disclosure about accounting policy changes and their effects on previously reported financial data. The length is relatively short (2164 characters), and it is a formal announcement rather than a full report. This fits the category of a Regulatory Filing (RNS), as it is a compliance disclosure about accounting policy changes without full financial statements or comprehensive report content.
2024-04-23 Chinese
德恒上海律师事务所关于华蓝集团股份公司2022年限制性股票激励计划回购注销及作废部分限制性股票相关事项的法律意见
Regulatory Filings Classification · 95% confidence The document is a legal opinion issued by a law firm (德恒上海律师事务所) regarding the 2022 restricted stock incentive plan of 华蓝集团股份公司. It discusses the repurchase, cancellation, and invalidation of certain restricted stocks under the incentive plan. The document includes detailed legal analysis, references to company law, securities law, and regulatory requirements, and confirms compliance with relevant procedures. It is not a financial report, earnings release, or management discussion, but a legal opinion related to corporate governance and stock incentive matters. This type of document fits best under 'Regulatory Filings' (RNS) as it is a legal compliance and disclosure document rather than a financial report or announcement of voting results or capital changes. The document length (8670 characters) and content confirm it is a substantive legal opinion, not a brief announcement or certification letter. Therefore, the classification is RNS with high confidence.
2024-04-23 Chinese
2023年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled '2023 年监事会工作报告' which translates to '2023 Supervisory Board Work Report' of 华蓝集团股份公司. It details the supervisory board's activities, oversight of company operations, financial status, internal controls, related party transactions, external guarantees, and use of raised funds for the year 2023. It includes detailed supervisory opinions on the company's compliance with laws, financial audits, and governance. The document is a comprehensive report on the supervisory board's work for the full fiscal year 2023, which aligns with the nature of a Management Report (MDA) that explains financial results, business trends, and outlook from management's perspective. It is not an Annual Report (10-K) or Audit Report (AR) because it focuses on supervisory board activities rather than full financial statements or audit opinions alone. It is not a short announcement or certification, so it is not RPA or RNS. Therefore, the best classification is Management Reports (MDA).
2024-04-23 Chinese
太平洋证券股份有限公司关于华蓝集团股份公司2023年度跟踪报告
Regulatory Filings Classification · 95% confidence The document is titled as a "2023年度跟踪报告" (2023 Annual Tracking Report) issued by a sponsoring institution (太平洋证券股份有限公司) regarding 华蓝集团股份公司. It details the sponsor's supervision work, including information disclosure review, governance oversight, fundraising supervision, and internal control checks. It also includes a summary of issues found and measures taken, company and shareholder commitments, and other related matters. The document is a detailed report on ongoing supervision and compliance monitoring rather than a full annual report or financial statement. It does not contain comprehensive financial statements or management discussion and analysis typical of Annual Reports (10-K) or Interim Reports (IR). It is also not a simple announcement or certification but a substantive supervisory report. This type of document aligns best with the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories. The document length is 2604 characters, which is relatively short but contains detailed supervisory content, so it is not a mere announcement (RPA). Therefore, the best classification is Regulatory Filings (RNS).
2024-04-23 Chinese
2023年度财务决算报告
Annual Report Classification · 95% confidence The document is titled as the "2023 年度财务决算报告" which translates to "2023 Annual Financial Settlement Report". It contains detailed financial data for the full year 2023, including income statement, balance sheet, cash flow statement, and notes on changes in financial items. It also mentions the audit by an accounting firm with an unqualified opinion, which is typical for an annual financial report. The document length is 4088 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or certification. Therefore, it is a full annual financial report rather than a mere announcement or certification. The content matches the definition of an Annual Report (10-K) as it covers the company's full financial performance for the year 2023. FY 2023
2024-04-23 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.